Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

ClinicalTrials.gov ID: NCT06812078

Public ClinicalTrials.gov record NCT06812078. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Idiopathic Hypersomnia (IH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Study identification

NCT ID
NCT06812078
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Takeda
Industry
Enrollment
96 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 6, 2025
Primary completion
Nov 29, 2026
Completion
Nov 29, 2026
Last update posted
Jul 14, 2026

2025 – 2026

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Takeda Site 11 Redwood City California 94063 Recruiting
Takeda Site 10 Santa Ana California 92705 Recruiting
Takeda Site 27 Colorado Springs Colorado 80918 Recruiting
Takeda Site 19 Brandon Florida 33511 Recruiting
Takeda Site 14 Winter Park Florida 32789 Recruiting
Takeda Site 29 St Louis Missouri 63123 Recruiting
Takeda Site 16 Denver North Carolina 28037 Recruiting
Takeda Site 15 Huntersville North Carolina 28078-5082 Recruiting
Takeda Site 12 Cincinnati Ohio 45245 Recruiting
Takeda Site 17 Cincinnati Ohio 45245 Recruiting
Takeda Site 13 Columbia South Carolina 29201 Recruiting
Takeda Site 18 San Antonio Texas 78229 Recruiting
Takeda Site 28 Norfolk Virginia 23507 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06812078, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 14, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06812078 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →